Moving to fingolimod from natalizumab in multiple sclerosis-reply

JAMA Neurol. 2014 Jul 1;71(7):925. doi: 10.1001/jamaneurol.2014.1138.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Drug Substitution / methods*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Multiple Sclerosis / drug therapy*
  • Propylene Glycols / therapeutic use*
  • Sphingosine / analogs & derivatives*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Propylene Glycols
  • Sphingosine